DDrare: Database of Drug Development for Rare Diseases

Searched query = "Autoimmune hepatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZATHIOPRINE; Abatacept; Anti-BAFFR antibody; Anti-BAFFr antibody; Azathioprine; Budesonide; Calcium; Cannabidiol; Chloroquine; Chloroquine diphosphate; Chloroquine diphosphate 250mg; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine-A; Denosumab; EFALIZUMAB; Efalizumab; Erythropoietin; Gold; High protein high fiber diet; INTERLEUKIN 2; Ianalumab; Inflectra (Infliximab); Infliximab; Interleukin 2; JKB-122; JKB-122 in capsule or tablet form; LCP-Tacro (tacrolimus); MYCOPHENOLATE MOFETIL; Metronidazole; Minodronic acid; Mycophenolate; Mycophenolate Mofetil; Mycophenolate mofeti; Mycophenolate mofetil; Orbcel-C; Orencia® (Abatacept); PREDNISOLONE SODIUM SUCCINATE; Prednisolone; Prednisone; Preimplantation factor; Raptiva; Raptiva 100 mg/ml powder and solvent for solution for injection; Regulatory T cells; Risedronic acid; SPIF; Synthetic PreImplantation Factor; Tacrolimus; Treatment with azathioprin; Treatment with mycophenolat mofetil; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ursodeoxycholic acid combination of immunosuppressive agents; VAY736; Vitamin D; Zoledronic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04376528 (ClinicalTrials.gov)	May 30, 2020	3/5/2020	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy	Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy	Hepatitis, Autoimmune;Primary Biliary Cholangitis;Immunosuppression	Drug: Cyclosporin A;Drug: Mycophenolate Mofetil	West China Hospital	NULL	Not yet recruiting	18 Years	70 Years	All	89	Phase 4	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04376528
(ClinicalTrials.gov)

May 30, 2020

3/5/2020

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Duo to Nonresponse to Standard Therapy

Hepatitis, Autoimmune;Primary Biliary Cholangitis;Immunosuppression

Drug: Cyclosporin A;Drug: Mycophenolate Mofetil

West China Hospital

NULL

Not yet recruiting

18 Years

70 Years

All

Phase 4

NULL